{"schemaVersion":1,"profileUrl":"https://nowen.ai/agents/insilico-com","markdownUrl":"https://nowen.ai/agents/insilico-com.md","jsonUrl":"https://nowen.ai/agents/insilico-com.json","name":"Insilico Medicine","website":"https://insilico.com","industry":"Biotechnology","status":{"trust":"unclaimed","text":"Unclaimed: compiled by Nowen from public sources, not reviewed by the company"},"updatedAt":"2026-09-06T23:31:51.193Z","summary":"Insilico Medicine is a global clinical-stage biotech company using end-to-end generative AI to accelerate drug discovery and development.","description":"Insilico Medicine is a global, clinical-stage biotech company that applies end-to-end generative artificial intelligence to drug discovery and clinical development. By integrating biology, chemistry, and computational modeling, the company aims to shorten discovery timelines, reduce costs, and bring life-saving therapies to patients. The organization positions itself as a partner to pharmaceutical companies, academic institutions, and healthcare researchers seeking to leverage AI to identify novel targets, design candidate molecules, and advance clinical programs. With a distributed team across key regions and collaborations with leading industry players, it emphasizes global collaboration, transparency, and rigorous scientific validation. Its platform supports the full pipeline from target identification through lead optimization and preclinical evaluation, with a focus on aging-related diseases and fibrotic conditions among its activities. Insilico Medicine highlights its track record of programs progressing toward clinical stages and its partnerships with universities and industry groups, underscoring its commitment to advancing science, improving patient outcomes, and driving innovation in biotechnology through AI.","mission":"Our mission is to extend healthy productive longevity for everyone by transforming drug discovery and development with generative artificial intelligence.","directory":{"industryName":"Biotechnology","agentCount":9,"indexable":false,"hubUrl":"https://nowen.ai/industry/biotechnology"},"aiReaderFamilies":["Anthropic","Meta","Amazon"],"products":[{"name":"Pharma.ai","type":"Platform","url":"https://pharma.ai","summary":"Accelerates drug discovery through generative AI, integrating biology, chemistry, and clinical development.","description":"End-to-end generative AI platform for drug discovery and development across biology, chemistry, and clinical development. Pharma.ai combines PandaOmics for target discovery and Chemistry42 for molecule design to rapidly generate and validate novel drug candidates, enabling a self-generated AI-driven drug discovery pipeline that can reduce timelines and costs.","pricing":{},"features":[{"name":"End-to-end platform across biology, chemistry, and clinical development","value":"Streamline All Aspects","valueDescription":"Provides a comprehensive solution from target identification to clinical evaluation, enhancing efficiency and collaboration."},{"name":"Fully self-generated AI-driven drug discovery pipeline","value":"Generate Novel Therapeutics","valueDescription":"Facilitates the efficient advancement of internal drug candidates through innovative AI methodologies."},{"name":"Massive Data Resources from PandaOmics","value":"Leverage Extensive Databases","valueDescription":"Access a vast array of data sources to enhance target discovery and decision-making."},{"name":"AI-Driven Design from Generative Biologics","value":"Enhances Discovery Speed","valueDescription":"The AI algorithms significantly reduce the time required to identify and optimize biologic candidates, facilitating quicker development cycles."},{"name":"Generative AI for drug discovery","value":"Reduce Discovery Timelines","valueDescription":"Accelerates the identification of viable drug candidates, enhancing speed to market for life-saving therapies."},{"name":"Integrated PandaOmics and Chemistry42 components","value":"Leverage Advanced Tools","valueDescription":"Utilizes specialized software components to maximize discovery potential and molecular design efficiency."},{"name":"AI-Driven Multi-omic Analysis from PandaOmics","value":"Maximize Insights from Omics Data","valueDescription":"Derive actionable insights that enhance understanding of complex disease mechanisms."},{"name":"Robotics laboratory integration","value":"Automate Experimentation","valueDescription":"Utilizes robotics to perform experiments more quickly and precisely, feeding data to improve AI models."},{"name":"Multinational collaborations","value":"Leverage Global Expertise","valueDescription":"Cultivates partnerships that enhance resource sharing and scientific validation, advancing drug development efforts."}]},{"name":"Chemistry42","type":"Platform","url":"https://pharma.ai/chemistry42","summary":"Accelerates drug discovery by leveraging AI for molecule generation and optimization.","description":"AI-driven chemistry platform for generative drug discovery. Chemistry42 provides molecule generation, retrosynthesis planning, model training, and related chemistry workflows to accelerate lead generation and optimization.","pricing":{},"features":[{"name":"AI-driven molecule generation","value":"Creates Novel Compounds","valueDescription":"Uses advanced AI algorithms to explore chemical space and design unique molecular structures."},{"name":"Retrosynthesis planning","value":"Facilitates Synthesis Pathway Design","valueDescription":"Provides efficient strategies for synthesizing complex molecules, saving time in experimental workflows."},{"name":"Pharma.ai ecosystem integration","value":"Ensures Cross-Platform Compatibility","valueDescription":"Seamlessly connects with other Pharma.ai tools to enhance overall drug discovery processes."},{"name":"Alchemistry and ADMET","value":"Optimizes Molecular Properties","valueDescription":"Enhances compound efficacy and safety profiles through predictive analysis."}]},{"name":"PreciousGPT","type":"Product","url":"https://pharma.ai/precious","summary":"PreciousGPT accelerates drug discovery using generative AI technology for enhanced research outcomes.","description":"Utilizing advanced generative AI techniques, PreciousGPT enhances drug discovery, offering innovative solutions for scientific research and targeted therapies. The platform integrates extensive biological and chemical data to provide actionable insights, aiding researchers and pharmaceutical companies in accelerating the development of life-saving medications.","pricing":{},"features":[{"name":"Generative AI Algorithms","value":"Design Innovative Drug Candidates","valueDescription":"Enables the creation of unique drug candidates by leveraging vast biological and chemical datasets, improving the odds of successful therapeutic outcomes."},{"name":"Patient-Centric Focus","value":"Address High Unmet Needs","valueDescription":"Focuses on developing therapeutic candidates aimed at conditions such as aging-related diseases and fibrosis, showcasing its commitment to improving patient outcomes."},{"name":"Collaborative Research Environment","value":"Facilitate Research Collaboration","valueDescription":"Supports partnerships that empower researchers to share insights and accelerate the progress of drug development."}]},{"name":"Nach01","type":"Product","url":"https://pharma.ai/nach01","summary":"Nach01 is an AI-generated cancer treatment inhibitor aimed at improving outcomes in hard-to-treat tumors.","description":"Nach01 is an AI-driven small molecule inhibitor showing significant promise for treating various types of cancer, including tumors that are resistant to current therapies. With a focus on precision targeting, it leverages Insilico Medicine's advanced generative AI platform for discovery and development, streamlining the drug creation process and enhancing efficacy and safety profiles.","pricing":{},"features":[{"name":"AI-Driven Design","value":"Enhances Treatment Efficacy","valueDescription":"Nach01 targets specific pathways in cancer cells, leading to improved treatment responses, especially in resistant cancers."},{"name":"Preclinical Success","value":"Proven Efficacy","valueDescription":"In vivo studies show significant tumor reduction, reinforcing its promise as a therapeutic agent."},{"name":"Focused on Hard-to-Treat Tumors","value":"Addresses Unmet Medical Need","valueDescription":"Nach01 aims to provide new treatment avenues for patients with limited options, enhancing survival rates."}]},{"name":"General Solutions","type":"Other","url":"https://pharma.ai/general","summary":"Integrates various tools for streamlining drug discovery processes.","description":"A collection of tools and platforms designed to facilitate the drug discovery process, enhancing efficiency and collaboration between various stakeholders in research and development.","pricing":{},"features":[{"name":"Comprehensive Integration","value":"Unify Drug Discovery Efforts","valueDescription":"Streamlines collaboration between different research teams, enabling them to work together on drug discovery projects effectively."},{"name":"Enhanced Data Sharing","value":"Boost Research Collaboration","valueDescription":"Encourages comprehensive data sharing practices, allowing teams to make informed decisions based on collective insights."}]}],"audiences":[],"segments":[{"name":"Generative chemistry and de novo small-molecule discovery","description":"Capabilities that generate novel small-molecule candidates using generative AI to accelerate hit identification and lead generation.","color":1,"productNames":["Chemistry42","Pharma.ai"]},{"name":"Target discovery and multi-omics analytics","description":"AI-driven target identification and multi-omic analysis to prioritize biological targets and hypotheses from large disease and omics datasets.","color":2,"productNames":["Pharma.ai"]},{"name":"Preclinical candidate optimization and ADMET prediction","description":"In silico property optimization and ADMET modeling to improve potency, selectivity, and developability prior to experimental testing.","color":3,"productNames":["Chemistry42","Pharma.ai"]},{"name":"Retrosynthesis and synthetic route planning","description":"Automated planning of synthetic routes and retrosynthetic analysis to support practical synthesis of designed molecules.","color":4,"productNames":["Chemistry42"]},{"name":"Generative AI research assistants and collaborative research platforms","description":"Generative AI interfaces and collaborative environments that accelerate research workflows, enable data sharing, and support cross-team collaboration.","color":5,"productNames":["PreciousGPT","General Solutions","Pharma.ai"]},{"name":"AI-driven laboratory automation and robotics","description":"Automation and robotics integrated with AI to execute experiments, generate high-throughput data, and close the design-make-test-analyze loop.","color":6,"productNames":["Pharma.ai"]},{"name":"AI-designed clinical-stage small-molecule therapeutics","description":"Clinical- and preclinical-stage therapeutic candidates discovered or designed using generative AI approaches for specific indications.","color":7,"productNames":["Nach01"]}],"faq":[],"comparisons":[],"sources":[{"url":"https://insilico.com","text":"Insilico Medicine"},{"url":"https://pharma.ai","text":"Pharma.ai"},{"url":"https://pharma.ai/chemistry42","text":"Chemistry42"},{"url":"https://pharma.ai/precious","text":"PreciousGPT"},{"url":"https://pharma.ai/nach01","text":"Nach01"},{"url":"https://pharma.ai/general","text":"General Solutions"}]}